Evidence map›Paper›PMID 27558903›Full record

ArticleBMJ open2016

Costs associated with functional gastrointestinal disorders and related signs and symptoms in infants: a systematic review protocol.

Julie Glanville, Thomas Ludwig, Carlos Lifschitz, James Mahon, Mohamad Miqdady, Miguel Saps, Seng Hock Quak, Irene Lenoir-Wijnkoop, Mary Edwards, Hannah Wood and 1 more

Erratum issuedAbstract read
In one paragraph

Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Julie GlanvilleYork Health Economics Consortium, University of York, York, UK.
Thomas LudwigNutricia Research, Utrecht, The Netherlands.
Carlos LifschitzHospital Italiano, Buenos Aires, Argentina.
James MahonYork Health Economics Consortium, University of York, York, UK.
Mohamad MiqdadyPediatric Gastroentrology, Hepatology and Nutrition Division, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Miguel SapsNationwide Children's Hospital, Columbus, Ohio, USA.
Seng Hock QuakNational University of Singapore, Singapore, Singapore.
Irene Lenoir-WijnkoopUniversity of Utrecht, Utrecht, The Netherlands.
Mary EdwardsYork Health Economics Consortium, University of York, York, UK.ORCID 0000-0002-2071-9990
Hannah WoodYork Health Economics Consortium, University of York, York, UK.
Hania SzajewskaDepartment of Paediatrics, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFunctional gastrointestinal disorders (FGIDs) and FGID-related signs and symptoms have a fundamental impact on the psychosocial, physical and mental well-being of infants and their parents alike. Recent reviews and studies have indicated that FGIDs and related signs and symptoms may also have a substantial impact on the budgets of third-party payers and/or parents. The objective of this systematic review is to investigate these costs. METHODS AND ANALYSIS: The population of interest is healthy term infants (under 12 months of age) with colic, regurgitation and/or functional constipation. Outcomes of interest will include the frequency and volume of reported treatments, the cost to third-party payers and/or parents for prescribed or over the counter treatments, visits to health professionals and changes in infant formula purchases, and the loss of income through time taken off work and out of pocket costs. Relevant studies will be identified by searching databases from 2005 onwards (including MEDLINE, EMBASE, PsycINFO, NEXIS, DARE, Health Technology Assessment database, National Health Service Economic Evaluation Database and others), conferences from the previous 3 years and scanning reference lists of eligible studies. Study selection, data extraction and quality assessment will be conducted by two independent reviewers and disagreements resolved in discussion with a third reviewer. Quality assessment will involve study design-specific checklists. Relevant studies will be summarised narratively and presented in tables. An overview of treatments and costs will be provided, with any geographical or other differences highlighted. An assessment of how the totals for cost differ across countries and elements that contribute to the differences will be generated. ETHICS AND DISSEMINATION: This is a systematic review of published studies that will be submitted for publication to a peer-reviewed journal. Ethical committee approval is not required. TRIAL REGISTRATION NUMBER: CRD42016033119.

Indexed as

Health Care CostsCost-Benefit AnalysisGastrointestinal DiseasesHumansInfantInsurance, Health, ReimbursementResearch DesignSystematic Reviews as TopicCLINICAL PHARMACOLOGY

Identifiers

PMID27558903
PMCPMC5013437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.